CLDF Title
Home | Contact Us | Bookmark
Embassy of Education  
Slide Library Webcasts Abstract Library LiverQ Academy National Conference
Back Drug & Device Development  
Available Topics
11-24-2014 Obeticholic acid promising against NASH liver damage
11-20-2014 Drug spending tops $1 trln on hepatitis C, cancer therapies -study
11-11-2014 Interferon-free regimen works against HCV in liver recipients
11-11-2014 AbbVie, Enanta drug shows potential in hep C genotype 4 patients
11-10-2014 INSIGHT-After hep C cure, companies target next big liver disease market
11-03-2014 Sofosbuvir-ledipasvir effective for relapsed HCV-1
09-30-2014 France uses tax to put pressure on hepatitis C drug prices
09-22-2014 Smartphone app may allow parents to screen newborns for jaundice
09-17-2014 Gilead's pancreas cancer drug fails mid-stage study
09-03-2014 Triptolide nanoformulation targets liver cancer cells
08-27-2014 ANALYSIS-InterMune drug may offer big upside to Roche if aimed at liver
08-15-2014 Achillion's hepatitis C drug cures all patients in mid-stage trial
08-12-2014 Intercept drug for non-alcoholic steatohepatitis found effective
08-06-2014 High HCV response rates with daclatasvir/asunaprevir: phase III data
07-23-2014 Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter
07-16-2014 Lanreotide slows progression of neuroendocrine tumors
07-11-2014 Senators ask Gilead to explain cost of Sovaldi hepatitis drug
07-07-2014 Japan approves all-oral hepatitis C dual drug regimen
06-17-2014 AbbVie all-oral hepatitis C therapy gets rapid EU review
06-13-2014 AbbVie says hepatitis C regimen gets nod for FDA priority review
06-11-2014 Lilly's Cyramza fails in liver cancer trial
05-16-2014 Drug for alpha-1 antitrypsin deficiency fails key trial
04-22-2014 Drug combination shows more efficacy against hepatitis C
04-14-2014 Drug for primary biliary cirrhosis proves highly effective in study
04-11-2014 Doctors welcome hepatitis C drug rivals
04-10-2014 Bristol-Myers hepatitis C treatment cures up to 90%: study
03-20-2014 Geron says FDA halts patient enrollment in another cancer trial
03-17-2014 Primary biliary cirrhosis drug effective in third late-stage trial
03-11-2014 Bayer's Nexavar misses target in liver cancer trial
03-04-2014 Dynavax withdraws EU marketing application for Hep B vaccine
03-04-2014 Panel favors continuation of tivantinib study for liver cancer
03-04-2014 Drug for nonalcoholic steatosis meets main goal in study
12-18-2013 Stellar hepatitis C data puts Gilead farther ahead of pack
12-10-2013 AbbVie says most in hepatitis C study show improvement


Be the first to know about our latest upcoming programs and events!


Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.